{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:56:29Z","timestamp":1789721789845,"version":"4.0.1"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Daiichi Sankyo, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The Tenosynovial giant cell tumor Observational Platform Project (TOPP) registry is an international prospective study that \u00adpreviously described the impact of diffuse-type tenosynovial giant cell tumour (D-TGCT) on patient-reported outcomes (PROs) from a baseline snapshot. This analysis describes the impact of D-TGCT at 2-year follow-up based on treatment strategies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Material and Methods<\/jats:title>\n                  <jats:p>TOPP was conducted at 12 sites (EU: 10; US: 2). Captured PRO measurements assessed at baseline, 1-year, and 2-year follow-ups were Brief Pain Inventory (BPI), Pain Interference, BPI Pain Severity, Worst Pain, EQ-5D-5L, Worst Stiffness, and \u00adPatient-Reported Outcomes Measurement Information System. Treatment interventions were no current\/planned treatment (Off-Treatment) and systemic treatment\/surgery (On-Treatment).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 176 patients (mean age: 43.5 years) were included in the full analysis set. For patients without active treatment strategy \u00ad(Off-Treatment) at baseline (n = 79), BPI Pain Interference (1.00 vs. 2.86) and BPI Pain Severity scores (1.50 vs. 3.00) were numerically favorable in patients remaining Off-Treatment compared with those who switched to an active treatment strategy at year 1. From 1-year to 2-year \u00adfollow-ups, patients who remained Off-Treatment had better BPI Pain Interference (0.57 vs. 2.57) and Worst Pain (2.0 vs. 4.5) scores compared with patients who switched to an alternative treatment strategy. In addition, EQ-5D VAS scores (80.0 vs. 65.0) were higher in patients who remained \u00adOff-Treatment between 1-year and 2-year follow-ups compared with patients who changed treatment strategy. For patients receiving systemic treatment at baseline, numerically favorable scores were seen in patients remaining on systemic therapy at 1-year follow-up: BPI Pain Interference (2.79 vs. 5.93), BPI Pain Severity (3.63 vs. 6.38), Worst Pain (4.5 vs. 7.5), and Worst Stiffness (4.0 vs. 7.5). From 1-year to 2-year follow-up, EQ-5D VAS scores (77.5 vs. 65.0) were higher in patients who changed from systemic treatment to a different treatment strategy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>These findings highlight the impact D-TGCT has on patient quality of life, and how treatment strategies may be influenced by these outcome measures. (ClinicalTrials.gov number: NCT02948088)<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad011","type":"journal-article","created":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T12:24:51Z","timestamp":1677932691000},"page":"e425-e435","source":"Crossref","is-referenced-by-count":13,"title":["Tenosynovial Giant Cell Tumor Observational Platform Project (TOPP) Registry: A 2-Year Analysis of Patient-Reported Outcomes and Treatment Strategies"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3406-6705","authenticated-orcid":false,"given":"Emanuela","family":"Palmerini","sequence":"first","affiliation":[{"name":"IRCCS Istituto Orthopedico Rizzoli , Bologna , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0802-1186","authenticated-orcid":false,"given":"John H","family":"Healey","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3338-5878","authenticated-orcid":false,"given":"Nicholas M","family":"Bernthal","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine at UCLA , Santa Monica, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5949-8120","authenticated-orcid":false,"given":"Sebastian","family":"Bauer","sequence":"additional","affiliation":[{"name":"West German Cancer Center, University of Duisburg-Essen , Essen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Schreuder","sequence":"additional","affiliation":[{"name":"Radboud University , Nijmegen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Leithner","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics and Trauma, Medical University of Graz , Graz , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7350-6916","authenticated-orcid":false,"given":"Javier","family":"Martin-Broto","sequence":"additional","affiliation":[{"name":"Fundac\u00edon Jim\u00e9nez D\u00edaz University Hospital, ATBSARC lab in General Hospital of Villalba, IIS-FJD , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Gouin","sequence":"additional","affiliation":[{"name":"Centre L\u00e9on B\u00e9rard , Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Lopez-Bastida","sequence":"additional","affiliation":[{"name":"University Castilla-La Mancha , Talavera de la Reina , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9270-8636","authenticated-orcid":false,"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center , Leiden , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8189-3055","authenticated-orcid":false,"given":"Eric L","family":"Staals","sequence":"additional","affiliation":[{"name":"IRCCS Istituto Orthopedico Rizzoli , Bologna , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Mercier","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Europe GmbH , Munich , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Laeis","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Europe GmbH , Munich , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5929-3798","authenticated-orcid":false,"given":"Xin","family":"Ye","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc. , Basking Ridge, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-7656","authenticated-orcid":false,"given":"Michiel","family":"van de Sande","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center , Leiden , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"issue":"6","key":"2023060913442528100_CIT0001","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.semarthrit.2010.07.005","article-title":"Pigmented villonodular synovitis: a retrospective single-center study of 122 cases and review of the literature","volume":"40","author":"Ottaviani","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"2023060913442528100_CIT0002","first-page":"e20.00028","article-title":"Management of tenosynovial giant cell tumor: a neoplastic and inflammatory disease","volume":"4","author":"Healey","year":"2020","journal-title":"J Am Acad Orthop Surg Glob Res Rev."},{"key":"2023060913442528100_CIT0003","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2016.04.022","article-title":"Diffuse-type tenosynovial giant cell tumour: current treatment concepts and future perspectives","volume":"63","author":"Staals","year":"2016","journal-title":"Eur J Cancer"},{"key":"2023060913442528100_CIT0004","first-page":"100","article-title":"Tenosynovial giant cell tumor, localized type.","volume-title":"WHO Classification of Tumours of Soft Tissue and Bone","author":"de Saint Aubain Somerhausen","year":"2013","edition":"4"},{"key":"2023060913442528100_CIT0005","first-page":"102","article-title":"Tenosynovial giant cell tumour, diffuse type.","volume-title":"WHO Classification of Tumours of Soft Tissue and Bone","author":"de Saint Aubain Somerhausen","year":"2013","edition":"4"},{"issue":"2","key":"2023060913442528100_CIT0006","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/his.13744","article-title":"Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?","volume":"74","author":"Mastboom","year":"2019","journal-title":"Histopathology"},{"issue":"10","key":"2023060913442528100_CIT0007","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.3899\/jrheum.160816","article-title":"Tenosynovial giant cell tumor: incidence, prevalence, patient characteristics, and recurrence. A Registry-based Cohort Study in Denmark","volume":"44","author":"Ehrenstein","year":"2017","journal-title":"J Rheumatol"},{"issue":"1","key":"2023060913442528100_CIT0008","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s41687-019-0099-0","article-title":"The measurement of physical functioning among patients with tenosynovial giant cell tumor (TGCT) using the Patient-Reported Outcomes Measurement Information System (PROMIS)","volume":"3","author":"Gelhorn","year":"2019","journal-title":"J Patient Rep Outcomes"},{"issue":"6","key":"2023060913442528100_CIT0009","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1080\/17453674.2017.1361126","article-title":"Higher incidence rates than previously known in tenosynovial giant cell tumors","volume":"88","author":"Mastboom","year":"2017","journal-title":"Acta Orthop"},{"issue":"5","key":"2023060913442528100_CIT0010","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1148\/rg.285085134","article-title":"Pigmented villonodular synovitis: radiologic-pathologic correlation","volume":"28","author":"Murphey","year":"2008","journal-title":"Radiographics"},{"issue":"8","key":"2023060913442528100_CIT0011","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1302\/0301-620X.96B8.33608","article-title":"Functional outcome and quality of life after the surgical treatment for diffuse-type giant-cell tumour around the knee: a retrospective analysis of 30 patients","volume":"96-b","author":"van der Heijden","year":"2014","journal-title":"Bone Joint J."},{"issue":"4","key":"2023060913442528100_CIT0012","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/jso.23220","article-title":"A multidisciplinary approach to giant cell tumors of tendon sheath and synovium\u2014a critical appraisal of literature and treatment proposal","volume":"107","author":"van der Heijden","year":"2013","journal-title":"J Surg Oncol"},{"issue":"4","key":"2023060913442528100_CIT0013","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/CCO.0b013e328347e1e3","article-title":"Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis","volume":"23","author":"Ravi","year":"2011","journal-title":"Curr Opin Oncol"},{"issue":"2","key":"2023060913442528100_CIT0014","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11864-015-0385-x","article-title":"Current systemic treatment options for tenosynovial giant cell tumor\/pigmented villonodular synovitis: targeting the CSF1\/CSF1R axis","volume":"17","author":"Brahmi","year":"2016","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"2023060913442528100_CIT0015","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2014.11.001","article-title":"Tenosynovial giant cell tumour\/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors","volume":"51","author":"Palmerini","year":"2015","journal-title":"Eur J Cancer"},{"issue":"11","key":"2023060913442528100_CIT0016","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1007\/s11999-009-0922-7","article-title":"Outcomes after excision of pigmented villonodular synovitis of the knee","volume":"467","author":"Sharma","year":"2009","journal-title":"Clin Orthop Relat Res"},{"issue":"8","key":"2023060913442528100_CIT0017","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1158\/1535-7163.MCT-16-0866","article-title":"Colony-stimulating factor 1 receptor blockade inhibits tumor growth by altering the polarization of tumor-associated macrophages in hepatocellular carcinoma","volume":"16","author":"Ao","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2023060913442528100_CIT0018","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40425-017-0257-y","article-title":"Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy","volume":"5","author":"Cannarile","year":"2017","journal-title":"J ImmunoTher Cancer"},{"issue":"16","key":"2023060913442528100_CIT0019","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s40265-019-01210-0","article-title":"Pexidartinib: first approval","volume":"79","author":"Lamb","year":"2019","journal-title":"Drugs"},{"key":"2023060913442528100_CIT0020","volume-title":"Turalio (pexidartinib) capsules, for oral use [prescribing information]","year":"2022"},{"key":"2023060913442528100_CIT0021","article-title":"National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: soft tissue sarcoma\u2014version 2.2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/sarcoma.pdf. Accessed February 2, 2023."},{"issue":"5","key":"2023060913442528100_CIT0022","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S1470-2045(18)30143-8","article-title":"Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial","volume":"19","author":"Gelderblom","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"2023060913442528100_CIT0023","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1186\/s12885-018-5188-6","article-title":"Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy","volume":"18","author":"Nakayama","year":"2018","journal-title":"BMC Cancer."},{"issue":"7","key":"2023060913442528100_CIT0024","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1302\/0301-620X.94B7.28927","article-title":"The management of diffuse-type giant cell tumour (pigmented villonodular synovitis) and giant cell tumour of tendon sheath (nodular tenosynovitis)","volume":"94","author":"van der Heijden","year":"2012","journal-title":"J Bone Joint Surg Br"},{"issue":"1","key":"2023060913442528100_CIT0025","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13023-021-01820-6","article-title":"The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study","volume":"16","author":"Bernthal","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"2023060913442528100_CIT0026","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1002\/jso.27067","article-title":"A prospective real-world study of the diffuse-type tenosynovial giant cell tumor patient journey: a 2-year observational analysis","volume":"126","author":"Bernthal","year":"2022","journal-title":"J Surg Oncol"},{"key":"2023060913442528100_CIT0027"},{"key":"2023060913442528100_CIT0028","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/01.blo.0000224051.01873.fb","article-title":"What affects the recurrence and clinical outcome of pigmented villonodular synovitis?","volume":"450","author":"Chiari","year":"2006","journal-title":"Clin Orthop Relat Res"},{"issue":"5","key":"2023060913442528100_CIT0029","doi-asserted-by":"crossref","first-page":"e000914","DOI":"10.1136\/esmoopen-2020-000914","article-title":"Unravelling the heterogeneity of soft tissue and bone sarcoma patients\u2019 health-related quality of life: a systematic literature review with focus on tumour location","volume":"5","author":"den Hollander","year":"2020","journal-title":"ESMO Open."},{"issue":"11","key":"2023060913442528100_CIT0030","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1093\/rheumatology\/keu230","article-title":"Long-term follow-up results of primary and recurrent pigmented villonodular synovitis","volume":"53","author":"Verspoor","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"2023060913442528100_CIT0031","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.clinthera.2016.03.008","article-title":"Patient-reported symptoms of tenosynovial giant cell tumors","volume":"38","author":"Gelhorn","year":"2016","journal-title":"Clin Ther."},{"issue":"4","key":"2023060913442528100_CIT0032","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/CCO.0000000000000853","article-title":"Treatment updates on tenosynovial giant cell tumor","volume":"34","author":"Palmerini","year":"2022","journal-title":"Curr Opin Oncol"},{"issue":"10197","key":"2023060913442528100_CIT0033","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"2023060913442528100_CIT0034","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1302\/0301-620X.101B3.BJJ-2018-0804.R1","article-title":"The effect of surgery in tenosynovial giant cell tumours as measured by patient-reported outcomes on quality of life and joint function","volume":"101-b","author":"Verspoor","year":"2019","journal-title":"Bone Joint J."},{"issue":"1","key":"2023060913442528100_CIT0035","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/CORR.0000000000002335","article-title":"Pexidartinib provides modest pain relief in patients with tenosynovial giant cell tumor: results from ENLIVEN","volume":"481","author":"Healey","year":"2022","journal-title":"Clin Orthop Relat Res"},{"issue":"4","key":"2023060913442528100_CIT0036","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/17453674.2021.1922161","article-title":"Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial","volume":"92","author":"van de Sande","year":"2021","journal-title":"Acta Orthop"},{"key":"2023060913442528100_CIT0037","first-page":"7768764","article-title":"Complementary effects of surgery and pexidartinib in the management of patients with complex diffuse-tenosynovial giant cell tumor","volume":"2022","author":"Bernthal","year":"2022","journal-title":"Case Rep Orthop."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/6\/e425\/50514549\/oyad011.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/6\/e425\/50514549\/oyad011.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T14:55:47Z","timestamp":1686322547000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/6\/e425\/7069289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,3,3]]},"published-print":{"date-parts":[[2023,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad011","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6,1]]},"published":{"date-parts":[[2023,3,3]]}}}